Synergistic Combinations for Enhanced Inflammatory Bowel Disease Treatment
Legal Citation
Summary of the Inventive Concept
Integrating peripheral nerve stimulation with AI, IoT, blockchain, and new materials to create a more effective and personalized treatment system for inflammatory bowel disease.
Background and Problem Solved
The original patent disclosed systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation. However, these methods have limitations in terms of data management, predictive analytics, and personalized treatment. The new inventive concept addresses these limitations by combining peripheral nerve stimulation with emerging technologies to create a more comprehensive and effective treatment system.
Detailed Description of the Inventive Concept
The new inventive concept consists of a peripheral nerve stimulator configured to modulate autonomic tone, which is integrated with a blockchain-based patient data management module for secure data storage and sharing. An AI-powered predictive analytics engine optimizes stimulation parameters based on patient response. Additionally, the system may include an IoT-enabled sensor module for monitoring physiological parameters and a cloud-based AI platform for analyzing sensor data and adjusting stimulation parameters. Alternatively, a new material-based implantable device can be used for delivering electrical stimulation signals. The synergistic combination of these technologies enables a more personalized and effective treatment approach.
Novelty and Inventive Step
The new claims introduce the novel combination of peripheral nerve stimulation with AI, IoT, blockchain, and new materials, which provides a significant improvement over the original patent. The integration of these technologies enables a more comprehensive and personalized treatment system, which is not obvious from the original patent.
Alternative Embodiments and Variations
Other embodiments of the inventive concept may include using different types of sensors or data analytics platforms, integrating with electronic health records, or incorporating machine learning algorithms for predictive modeling. Variations may also include using different materials or implantable devices, or incorporating additional features such as patient feedback mechanisms or remote monitoring capabilities.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the treatment of inflammatory bowel disease, with potential applications in personalized medicine, telehealth, and digital therapeutics. The target market includes pharmaceutical companies, medical device manufacturers, and healthcare providers seeking innovative solutions for chronic disease management.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering and medical device technologies focused on neuromodulation for treating inflammatory conditions, specifically gastrointestinal disorders. Requires expertise in electrical stimulation, physiological signal processing, and medical treatment methodologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical device researcher with advanced degrees, knowledge of nerve stimulation techniques, familiarity with AI/IoT technologies, and understanding of inflammatory disease treatment strategies
Obviousness Rationale
A person of ordinary skill would recognize that integrating modern digital technologies with the existing peripheral nerve stimulation approach represents a predictable evolution of the treatment methodology. The core nerve stimulation technique remains fundamentally unchanged, while adding data analytics, monitoring, and personalization features represents an incremental technological improvement. These extensions would be considered obvious combinations of known techniques in medical device engineering and digital health technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,778 |
|---|---|
| Title | Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation |
| Assignee(s) | Cala Health, Inc. |